**Figure S1** Adjusted mean change from baseline in DAS28 (CRP) over the double-blind period (A) and combined double-blind and open-label periods (B) in the total population (ITT analysis). Error bars represent 95% CI. Hash signs in panel A indicate adjusted differences in mean change for abatacept versus placebo for which 95% CI do not contain zero. In the double-blind period analysis (panel A), early escape patients were set to missing at weeks 20 and 24. In the combined double-blind and open-label period analysis (panel B), measurements for early escape patients at weeks 20, 24, 28, 36 and 44 are actual measurements at weeks 4, 8, 12, 20 and 28 of open-label abatacept treatment. The continued improvements in DAS28 (CRP) from week 16 to week 24 in the placebo group reflects the mixed population of early escape patients who received abatacept between weeks 16 and 24 and non-early escape patients who received placebo to week 24. CI, confidence interval; DAS, Disease Activity Score; ITT, intent to treat.

